IN8BIO Reports Q1 2025 Net Loss of $5.6M, EPS Improves to $0.07 Loss from $0.20, Cash Position at $11.9M

Reuters
08 May
IN8BIO Reports Q1 2025 Net Loss of $5.6M, EPS Improves to $0.07 Loss from $0.20, Cash Position at $11.9M

IN8BIO Inc., a clinical-stage biopharmaceutical company, reported its financial results for the first quarter ending March 31, 2025. The company recorded a net loss of $5.6 million, or $0.07 per common share, an improvement from the net loss of $8.6 million, or $0.20 per share, in the same period the previous year. General and administrative expenses decreased to $2.7 million from $3.7 million, attributed to cost savings in personnel, insurance premiums, and professional services. The company's cash position was $11.9 million as of March 31, 2025, slightly down from $13.0 million in the previous year. In April 2025, IN8BIO raised additional gross proceeds of $1.9 million. On the operational front, IN8BIO continued to make strides in its gamma-delta T cell therapies. The Phase 1 clinical data for INB-100 showed promising long-term remission results in Acute Myeloid Leukemia patients, with all remaining relapse-free at a median follow-up of 20.1 months. The company also presented new data on its INB-600 platform at the American Association for Cancer Research 2025 Annual Meeting, highlighting potential applications in oncology and autoimmune diseases. Upcoming milestones include an oral presentation of INB-200 at the American Society of Clinical Oncology 2025 Annual Meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IN8BIO Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950170-25-065603), on May 07, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10